Drugs / AL-78898A
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00473928 | May 2007 → Feb 2010 | age-related macular degeneration | Potentia Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01603043 | Jun → Nov 2012 | diffuse secondary choroid atrophy | Alcon Research | Terminated | No outcome recorded |
| Phase 2 | NCT01157065 | Jun 2011 → Apr 2012 | wet macular degeneration | Alcon Research | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Al-78898A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01603043 ↗ |
| Known as | (trp(me)4)-ac-compstatin | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594457 ↗ |
| Known as | 4(1mew) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594457 ↗ |
| Known as | Compstatin analog 4(1mew) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594457 ↗ |
| Known as | POT-4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00473928 ↗ |
| Action | Inhibit | “Complement C3 inhibitor” CHEMBL4594457 ↗ |
| Route | Intravitreal | “Single intravitreal injection.” NCT00473928 ↗ |
| Target | C3 | “Complement C3 inhibitor” CHEMBL4594457 ↗ |